Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway

Endocrinology. 2013 Oct;154(10):3680-9. doi: 10.1210/en.2013-1002. Epub 2013 Sep 11.

Abstract

Metformin exhibits diverse protective effects against diabetic complications, such as bone loss. Here, we investigated the effect of metformin on vascular calcification, another type 2 diabetes complication. In female rat aortic smooth muscle cells (RASMCs), we observed that metformin significantly alleviated β-glycerophosphate-induced Ca deposition and alkaline phosphatase activity, corresponding with reduced expression of some specific genes in osteoblast-like cells, including Runx2 and bone morphogenetic protein-2, and positive effects on α-actin expression, a specific marker of smooth muscle cells. Mechanistic analysis showed that phosphorylation levels of both AMP-activated protein kinase (AMPK) and endothelial nitric oxide synthase (eNOS) were increased with NO overproduction. After inhibition of either AMPK or eNOS with the pharmacologic inhibitors, compound C or Nω-Nitro-L-arginine methyl ester, NO production was lowered and metformin-meditated vascular protection against β-glycerophosphate-induced Ca deposition was removed. Our results support that metformin prevents vascular calcification via AMPK-eNOS-NO pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / antagonists & inhibitors
  • AMP-Activated Protein Kinases / chemistry
  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Aorta / cytology
  • Aorta / drug effects*
  • Aorta / metabolism
  • Aorta / pathology
  • Cell Transdifferentiation / drug effects
  • Cells, Cultured
  • Diabetic Angiopathies / chemically induced
  • Diabetic Angiopathies / metabolism
  • Diabetic Angiopathies / pathology
  • Diabetic Angiopathies / prevention & control
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / adverse effects
  • Female
  • Glycerophosphates / adverse effects
  • Glycerophosphates / antagonists & inhibitors
  • Hypoglycemic Agents / antagonists & inhibitors
  • Hypoglycemic Agents / pharmacology*
  • Metformin / antagonists & inhibitors
  • Metformin / pharmacology*
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Muscle, Smooth, Vascular / pathology
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / chemistry
  • Nitric Oxide Synthase Type III / metabolism*
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / adverse effects
  • Protein Processing, Post-Translational / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects
  • Vascular Calcification / chemically induced
  • Vascular Calcification / metabolism
  • Vascular Calcification / pathology
  • Vascular Calcification / prevention & control*

Substances

  • Enzyme Inhibitors
  • Glycerophosphates
  • Hypoglycemic Agents
  • Protein Kinase Inhibitors
  • Nitric Oxide
  • Metformin
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • AMP-Activated Protein Kinases
  • beta-glycerophosphoric acid